Appointment dossier — Pancreatic Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Pancreatic Cancer
- Fuzuloparib — Review evidence · 1 positive · PMID 34118019
- Relacorilant — Review evidence · 1 positive · PMID 42334771
- Gemcitabine — Animal evidence · 0 positive / 1 negative-mixed · PMID 34274382
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07232875 · Phase 3 — HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer (China)
- NCT04543071 · Phase 2 — Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma (United States)
- NCT06605430 · Phase 2 — Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer (United States)
- NCT07597772 · Early Phase 1 — Preliminary Trial of SNA014 for Pancreatic Cancer (China)
- NCT07059884 — Distance-Based Exercise to Preserve Function and Prevent Disability (United States)
- NCT04575363 — RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer (France)
- NCT07307664 — Increasing Germline Genetic Testing for Patients With Cancer (United States)
- NCT06026943 — Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer (Italy)
- NCT03311776 — BIOmarkers in Patients With Pancreatic Cancer ("BIOPAC") (Denmark)
- NCT06160323 — Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer (Hong Kong)
- NCT06717295 — The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling (Argentina)
- NCT05802394 — The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer (China)
- NCT05845801 — Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer (Italy)
- NCT07440290 · Phase 2 / Phase 3 — DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. (United Kingdom)
- NCT06926075 · Phase 1 / Phase 2 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours (Australia)
- NCT07020221 · Phase 1 / Phase 2 — A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors (United States)
- NCT06179160 · Phase 1 — A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (United States)
- NCT01915225 — Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer (United States)
Most-relevant first: trials that name Pancreatic Cancer, then broader trials you may still qualify for. 888 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT07232875), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?